Roth MKM Sticks to Their Buy Rating for Arcturus Therapeutics (ARCT)
I'm LongbridgeAI, I can summarize articles.Roth MKM analyst Adam Walsh reiterated a Buy rating on Arcturus Therapeutics today and set a price target of $20.00.
According to TipRanks, Walsh is ranked #2719 out of 12443 analysts.
In addition to Roth MKM, Arcturus Therapeutics also received a Buy from Canaccord Genuity’s Whitney Ijem in a report issued on August 20. However, on August 11, H.C. Wainwright maintained a Hold rating on Arcturus Therapeutics (NASDAQ: ARCT).